Literature DB >> 7827892

Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head.

J H Allema1, M E Reinders, T M van Gulik, D J van Leeuwen, L T de Wit, P C Verbeek, D J Gouma.   

Abstract

Of 176 patients with carcinoma of the pancreatic head region 156 underwent standard pancreatoduodenectomy (group 2) and 20 with macroscopic suspicion of invasion of the portal vein or superior mesenteric vein (SMV) underwent pancreatoduodenectomy with partial resection of the portal vein or SMV (group 1). In 16 patients in group 1 end-to-end anastomosis was used for reconstruction of the vein. The morbidity rate in groups 1 and 2 was similar (55 versus 63 per cent). The hospital mortality rate was 15 per cent in group 1 and 7 per cent in group 2 (P = 0.22). Histological examination confirmed tumour invasion of the portal vein or SMV in ten patients in group 1. Invasion of the portal vein or SMV was significantly more frequent in patients with pancreatic cancer than in those with distal bile duct or ampullary carcinoma. Of the 20 patients in group 1 only three underwent curative resection with tumour-free margins. The median survival time after resection of the portal vein or SMV was 8 months; the 2-year survival rate was 19 per cent. Comparison of survival in group 1 with survival in subgroups of patients undergoing standard pancreatoduodenectomy, matched for all histological parameters, showed no significant difference. It is concluded that partial resection of the portal vein or SMV in patients undergoing pancreatoduodenectomy who are suspected of having tumour invasion of the portal vein or SMV does not improve either the rate of curative resection or survival.

Entities:  

Mesh:

Year:  1994        PMID: 7827892     DOI: 10.1002/bjs.1800811126

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  41 in total

1.  Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis.

Authors:  Yanming Zhou; Zhiming Zhang; Yujian Liu; Bin Li; Donghui Xu
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

Review 2.  Borderline resectable pancreatic cancer: definitions and management.

Authors:  Nicole E Lopez; Cristina Prendergast; Andrew M Lowy
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Oncological problems in pancreatic cancer surgery.

Authors:  Akimasa Nakao; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Shuji Nomoto; Yasuhiro Kodera; Soichiro Inoue; Shin Takeda
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 4.  Anticoagulation policy after venous resection with a pancreatectomy: a systematic review.

Authors:  Manju D Chandrasegaram; Guy D Eslick; Wayne Lee; Mark E Brooke-Smith; Rob Padbury; Christopher S Worthley; John W Chen; John A Windsor
Journal:  HPB (Oxford)       Date:  2013-12-18       Impact factor: 3.647

5.  Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.

Authors:  Hop S Tran Cao; Alpana Balachandran; Huamin Wang; Graciela M Nogueras-González; Christina E Bailey; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Gauri Varadhachary; Christopher H Crane; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2013-10-16       Impact factor: 3.452

Review 6.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

Review 7.  Pancreatic adenocarcinoma: why and when should it be resected?

Authors:  D Ravichandran; C D Johnson
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

8.  Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.

Authors:  V K Mehta; G Fisher; J A Ford; J C Poen; M A Vierra; H Oberhelman; J Niederhuber; J A Bastidas
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

Review 9.  Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis.

Authors:  Markus Schäfer; Beat Müllhaupt; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

10.  Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?

Authors:  L E Harrison; D S Klimstra; M F Brennan
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.